TisCRT-LAPC: A phase II study of tislelizumab combined with nab-paclitaxel and gemcitabine (AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC)

被引：0
|
作者：
Guo, Xi
Zhou, Yuhong
Ji, Yuan
Lou, Wenhui
Wu, Lili
Wang, Wenquan
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Radiol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16350
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
    Picozzi, Vincent J.
    Rocha, Flavio G.
    Helton, Scott
    Pishvaian, Michael J.
    Jackson, Patrick G.
    Mody, Kabir
    Asbun, Horacio
    Carney, Mairead
    Etheridge, Tina
    Neff, Thomas B.
    Porter, Seth
    Zhong, Ming
    Valone, Frank
    Kouchakji, Elias
    Imperial, Joanne C.
    Carrier, Ewa
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [22] Phase II study of pirfenidone combined with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer
    Guo, Guifang
    Li, Shengping
    Mao, Yize
    Yang, Qiuxia
    Yao, Zehui
    Wang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] EFFICACY OF GEMCITABINE/NAB-PACLITAXEL INDUCTION CHEMOTHERAPY FOLLOWED BY CHEMORADIOTHERAPY FOR UNRESECTABLE LOCALLY ADVANCED PANCREATIC CANCER
    Takada, Ryoji
    Ikezawa, Kenji
    Kiyota, Ryosuke
    Imai, Toshihiro
    Yutaro, Abe
    Fukutake, Nobuyasu
    Takatoshi, Nawa
    Katayama, Kazuhiro
    Ohkawa, Kazuyoshi
    GASTROENTEROLOGY, 2020, 158 (06) : S865 - S866
  • [24] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Tsujimoto, Akiko
    Sudo, Kentaro
    Nakamura, Kazuyoshi
    Kita, Emiri
    Hara, Ryusuke
    Takayama, Wataru
    Ishii, Hiroshi
    Yamaguchi, Taketo
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [25] Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
    Picozzi, Vincent J.
    Rocha, Flavio G.
    Helton, Scott
    Mody, Kabir
    Asbun, Horacio
    Pishvaian, Michael J.
    Jackson, Patrick G.
    Etheridge, Tina
    Carney, Mairead
    Neff, Thomas B.
    Porter, Seth
    Crans, Gerald
    Valone, Frank
    Shi, Wen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [26] Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
    Okusaka, T
    Ito, Y
    Ueno, H
    Ikeda, M
    Takezako, Y
    Morizane, C
    Kagami, Y
    Ikeda, H
    BRITISH JOURNAL OF CANCER, 2004, 91 (04) : 673 - 677
  • [27] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Akiko Tsujimoto
    Kentaro Sudo
    Kazuyoshi Nakamura
    Emiri Kita
    Ryusuke Hara
    Wataru Takayama
    Hiroshi Ishii
    Taketo Yamaguchi
    Scientific Reports, 9
  • [28] Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer
    T Okusaka
    Y Ito
    H Ueno
    M Ikeda
    Y Takezako
    C Morizane
    Y Kagami
    H Ikeda
    British Journal of Cancer, 2004, 91 : 673 - 677
  • [29] A phase 1 study of neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel, followed by concurrent chemoradiation with gemcitabine, sorafenib, and vorinostat in locally advanced pancreatic cancer
    Park, Haeseong
    Poklepovic, Andrew
    CANCER RESEARCH, 2014, 74 (19)
  • [30] Phase III PANOVA study of tumor treating fields (150 kHz) in combination with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC)
    Weinberg, Uri
    Farber, Ori
    Giladi, Moshe
    Bomzon, Zeev
    Kirson, Eilon
    CANCER RESEARCH, 2019, 79 (13)
12345